Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify the combined impact on bone loss as well as the
incidence of bone fractures in women with estrogen receptor (ER)-positive, early breast
cancer treated with an aromatase inhibitor (AI) either as first line therapy or as
maintenance therapy after initial treatment with chemotherapy, in real life clinical settings
in Greece.